Geerling G, Unterlauft J D, Kasper K, Schrader S, Opitz A, Hartwig D
Klinik für Augenheilkunde, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Deutschland.
Ophthalmologe. 2008 Jul;105(7):623-31. doi: 10.1007/s00347-008-1750-y.
Eye drops made from autologous serum have been increasingly used in the past decade to treat ocular surface disorders such as persistent epithelial defects and dry eye. Due to biologically active ingredients such as growth factors, vitamins, and nutrients, they can be used to lubricate the ocular surface and support epithelial wound healing. According to current legal requirements, they can be dispensed only for outpatient treatment if the producer has obtained a license from the appropriate local authorities. Therefore, the production and dispensing of autologous serum eye drops in Germany is currently limited to a very few institutions and their patients. We review the current evidence on the use of serum eye drops, recommend a standard protocol for their production, and describe a number of recently emerging alternative blood products for the treatment of ocular surface diseases along with their potential advantages and limitations.
在过去十年中,自体血清制成的眼药水越来越多地用于治疗眼部表面疾病,如持续性上皮缺损和干眼症。由于含有生长因子、维生素和营养物质等生物活性成分,它们可用于润滑眼部表面并支持上皮伤口愈合。根据现行法律要求,如果生产商已获得当地有关部门的许可,它们只能用于门诊治疗。因此,目前德国自体血清眼药水的生产和配发仅限于极少数机构及其患者。我们回顾了目前关于使用血清眼药水的证据,推荐了其生产的标准方案,并描述了一些最近出现的用于治疗眼部表面疾病的替代血液制品及其潜在的优点和局限性。